The HIV prevention landscape is set for transformation. health partners announced that Lenacapavir — a twice-yearly injectable proven to prevent nearly 100% of new infections — will be available for just $40 annually in low- and middle-income countries.

This landmark pricing agreement was reached through Unitaid, the Clinton Health Access Initiative (CHAI), and Wits RHI. Former U.S. President Bill Clinton hailed it as “a milestone in global public health,” while Rwanda’s Health Minister, Dr. Sabin Nsanzimana, stressed its significance for Africa, where over 1.3 million new infections occur each year.

With its affordability and unmatched efficacy, Lenacapavir could become a cornerstone of global strategies to end HIV/AIDS as a public health threat.